0001564590-22-007361.txt : 20220228 0001564590-22-007361.hdr.sgml : 20220228 20220228074639 ACCESSION NUMBER: 0001564590-22-007361 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220228 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALX ONCOLOGY HOLDINGS INC CENTRAL INDEX KEY: 0001810182 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850642577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39386 FILM NUMBER: 22683939 BUSINESS ADDRESS: STREET 1: 323 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-466-7125 MAIL ADDRESS: STREET 1: 323 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 alxo-8k_20220228.htm Q4'21 8-K/PR alxo-8k_20220228.htm
false 0001810182 0001810182 2022-02-28 2022-02-28

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 28, 2022

 

ALX ONCOLOGY HOLDINGS INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39386

85-0642577

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

323 Allerton Avenue,     

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 466-7125

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

ALXO

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On February 28, 2022, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

 

 

 

99.1

 

Press Release dated February 28, 2022

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ALX ONCOLOGY HOLDINGS INC.

 

 

 

 

Date: February 28, 2022

 

By:

/s/ Peter Garcia

 

 

 

Peter Garcia

 

 

 

Chief Financial Officer

 

 

 EX-99.1 2 alxo-ex991_6.htm EX-99.1 alxo-ex991_6.htm

 

Exhibit 99.1

 

ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

 

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided clinical development and operational highlights.

 

“ALX Oncology achieved key milestones in 2021 to advance our lead program, evorpacept, a next-generation CD47 blocker, through multiple clinical trials,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “Notable accomplishments included initiating two Phase 2 trials in head and neck squamous cell carcinoma (“HNSCC”) and presenting encouraging Phase 1b data from the ASPEN-01 trial in gastric/gastroesophageal junction (“GEJ”) cancer and HNSCC, along with early Phase 1a data from the ASPEN-02 trial in myelodysplastic syndromes (“MDS”). Data from these trials also showed evorpacept to be well tolerated when combined with anti-cancer antibodies and multi-agent chemotherapy regimens in solid tumors and with azacitidine in MDS.”

 

Dr. Pons added: “2022 is expected to be another productive year with the anticipated initiation of a randomized Phase 2/3 clinical trial of evorpacept in combination with trastuzumab, ramucirumab and paclitaxel in patients with 2nd line or greater gastric/GEJ cancer and the expected completion of enrollment and dose optimization data readout from our Phase 1b clinical trial of evorpacept in combination with azacitidine in patients with MDS. The design of evorpacept, with an inactive Fc, continues to set us apart from competing CD47 blockers to date. Our data suggest that evorpacept’s inactive Fc approach shows greater tolerability than CD47 blocking approaches using an active Fc domain, several of which have shown significant cytopenias in the clinic. Additionally, our initial clinical data show anti-tumor activity on par or better than other such agents.”

 

 

Anticipated Key Clinical Milestones for 2022

 

•

Initiation of a randomized Phase 2/3 clinical trial of evorpacept in combination with Herceptin® (trastuzumab), Cyramza® (ramucirumab) and paclitaxel in patients with 2nd line or greater gastric/GEJ cancer (ASPEN-06).

 

•

Dose optimization readout of a Phase 1b clinical trial of evorpacept in combination with azacitidine in patients with MDS (ASPEN-02).

 

•

Initiate and provide updates on investigator sponsored clinical trials with evorpacept.

 

•

Provide updates on ongoing collaboration with Zymeworks (NYSE: ZYME) in HER2-expressing breast cancer and other solid tumors.

 

•

Select development candidate(s) from preclinical pipeline.

 

 

 

Recent Clinical Developments for Evorpacept (ALX148)

•

U.S. Food and Drug Administration (“FDA”) Granted Orphan Drug Designation (“ODD”) for Evorpacept for the Treatment of Patients with Gastric/GEJ Cancer

 

o

In January 2022, ALX announced that the U.S. FDA granted ODD to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric/GEJ cancer.

•

Presented Initial Phase 1a Clinical Data in Combination with Azacitidine in Patients with MDS (ASPEN-02) at ASH

 

o

In December 2021, the Company presented initial clinical data from its ongoing trial evaluating evorpacept in combination with azacitidine for the treatment of patients with previously untreated higher-risk or relapsed or refractory MDS. The new data, shared in a poster at the 63rd American Society of Hematology (“ASH”) Annual Meeting [Abstract #2601], show that the combination of evorpacept and azacitidine is active and well-tolerated. Patient accrual is ongoing in the Phase 1b dose optimization part of the study.

•

Presented Updated Phase 1b Clinical Trial Data in Combination with Pembrolizumab with and without Chemotherapy in Patients with HNSCC and in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Patients with Gastric/GEJ Cancer (ASPEN-01) at SITC

 

o

In November 2021, updated results from Phase 1b study (ASPEN-01) evaluating patients with solid tumor malignancies were presented at the Society for Immunotherapy of Cancer’s 36th Anniversary Annual Meeting [Abstract #498]. ALX Oncology reported updated results from the gastric/GEJ cancer patient cohort receiving evorpacept plus trastuzumab plus chemotherapy, and from the head and neck squamous cell carcinoma patient cohort receiving evorpacept plus pembrolizumab with and without chemotherapy. Data showed robust and durable responses with emerging signs of clinical benefit in survival-based endpoints in patients with advanced solid tumors. All data reflected response evaluable patients as of September 1, 2021.

•

Initiation of a Phase 1a Clinical Trial in Combination with Venetoclax and Azacitidine in Acute Myeloid Leukemia (ASPEN-05)

 

o

In October 2021, the first patient was dosed in the Phase 1/2 ASPEN-05 study evaluating the combination of evorpacept with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (“AML”). The Phase 1 portion will characterize the safety of evorpacept in combination with venetoclax and azacitidine for the treatment of patients with relapsed/refractory AML and previously untreated AML who are not candidates for intensive induction therapy.

•

Initiation of a Phase 1b/2 Clinical Trial in Combination with Zanidatamab in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

 

o

In October 2021, Zymeworks and ALX Oncology dosed the first patient in an open-label, multi-center Phase 1b/2 clinical trial to evaluate the safety and efficacy of zanidatamab, Zymeworks’ lead HER2-targeted bispecific antibody, in combination with evorpacept in

 

 

 

patients with advanced HER2-positive breast cancer, HER2-low breast cancer and additional non-breast HER2-expressing solid tumors.

Recent Corporate Updates

•

Acquired Privately Held ScalmiBio Inc.: In October 2021, ALX Oncology acquired ScalmiBio which further expanded its pipeline with plans to develop novel antibody-drug conjugates (“ADCs”) based on ScalmiBio’s SHIELD platform.

Full Year and Fourth Quarter 2021 Financial Results:

•

Cash and Cash Equivalents: Cash and cash equivalents as of December 31, 2021 were $363.7 million. ALX Oncology believes its cash and cash equivalents is sufficient to fund planned operations through mid-2024.

•

Related-party Revenue: There was no related-party revenue for the three months ended December 31, 2021 and 2020. There was no related-party revenue for the year ended December 31, 2021, compared to $1.2 million for the prior-year period. The decrease in related-party revenue relates to the termination of the research and development agreement with Tallac Therapeutics, Inc. in July 2020.

•

Research and Development (“R&D”) Expenses: R&D expenses consist primarily of pre-clinical, clinical and manufacturing expenses related to the development of the Company’s current lead product candidate, evorpacept, and R&D employee-related expenses. These expenses for the three months ended December 31, 2021, were $20.9 million, compared to $12.1 million for the prior-year period. Expenses for the three months ended December 31, 2021 included $4.7 million of acquired in-process research and development expenses related to the acquisition of ScalmiBio. R&D expenses for the year ended December 31, 2021, were $60.2 million, compared to $29.0 million for the prior-year period.

•

General and Administrative (“G&A”) Expenses: G&A expenses consist primarily of administrative employee-related expenses, legal and other professional fees, patent filing and maintenance fees, and insurance. These expenses for the three months ended December 31, 2021, were $7.6 million, compared to $5.7 million for the prior-year period. G&A expenses for the year ended December 31, 2021, were $23.4 million, compared to $14.8 million for the prior-year period.

•

Net loss: GAAP net loss attributable to common stockholders was $28.4 million for the fourth quarter ended December 31, 2021, or $0.70 per basic and diluted share, as compared to a net loss of $18.8 million for the fourth quarter ended December 31, 2020, or $0.50 per basic and diluted share. GAAP net loss for the year ended December 31, 2021 was $83.5 million, or $2.07 per basic and diluted share, as compared to $50.9 million, or $2.76 per basic and diluted share, for the year ended December 31, 2020. Non-GAAP net loss was $22.8 million for the fourth quarter ended December 31, 2021, as compared to a net loss of $16.3 million for the fourth quarter ended December 31, 2020. Non-GAAP net loss for the year ended December 31, 2021 was $69.5 million, as compared to $43.8 million for the year ended December 31, 2020. A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and

 

 

solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

 

ALX ONCOLOGY HOLDINGS INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

Year Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Related-party revenue

 

$

—

 

 

$

—

 

 

$

—

 

 

$

1,182

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

20,894

 

 

 

12,142

 

 

 

60,170

 

 

 

28,961

 

General and administrative

 

 

7,578

 

 

 

5,683

 

 

 

23,385

 

 

 

14,809

 

Cost of services for related-party revenue

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,075

 

Total operating expenses

 

 

28,472

 

 

 

17,825

 

 

 

83,555

 

 

 

44,845

 

Loss from operations

 

 

(28,472

)

 

 

(17,825

)

 

 

(83,555

)

 

 

(43,663

)

Interest expense

 

 

(3

)

 

 

(151

)

 

 

(13

)

 

 

(811

)

Other income (expense), net

 

 

16

 

 

 

5

 

 

 

84

 

 

 

(404

)

Loss on early debt extinguishment

 

 

—

 

 

 

(621

)

 

 

—

 

 

 

(621

)

Loss before income taxes

 

 

(28,459

)

 

 

(18,592

)

 

 

(83,484

)

 

 

(45,499

)

Income tax benefit (provision)

 

 

21

 

 

 

(182

)

 

 

21

 

 

 

(241

)

Net loss and comprehensive loss

 

 

(28,438

)

 

 

(18,774

)

 

 

(83,463

)

 

 

(45,740

)

Cumulative dividends allocated to preferred stockholders

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(5,202

)

Net loss attributable to common stockholders

 

$

(28,438

)

 

$

(18,774

)

 

$

(83,463

)

 

$

(50,942

)

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(0.70

)

 

$

(0.50

)

 

$

(2.07

)

 

$

(2.76

)

Weighted-average shares of common stock used to

   compute net loss per share attributable to

   common stockholders, basic and diluted

 

 

40,527,314

 

 

 

37,642,897

 

 

 

40,308,050

 

 

 

18,485,343

 

 

 

 

 

Condensed Consolidated Balance Sheet Data

(unaudited)

(in thousands)

 

 

 

December 31,

2021

 

 

December 31,

2020

 

Cash and cash equivalents

 

$

363,667

 

 

$

434,219

 

Total assets

 

$

380,183

 

 

$

436,054

 

Total liabilities

 

$

17,134

 

 

$

6,209

 

Accumulated deficit

 

$

(201,985

)

 

$

(118,522

)

Total stockholders’ equity

 

$

363,049

 

 

$

429,845

 

 

GAAP to Non-GAAP Reconciliation

(unaudited)

(in thousands)

 

 

 

Three Months Ended

 

 

Year Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

GAAP net loss attributable to common stockholders, as

   reported

 

$

(28,438

)

 

$

(18,774

)

 

$

(83,463

)

 

$

(50,942

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

5,686

 

 

 

1,743

 

 

 

13,914

 

 

 

5,436

 

Accretion of term loan

 

 

—

 

 

 

82

 

 

 

—

 

 

 

421

 

Mark-to-market adjustment on financial instruments

 

 

—

 

 

 

—

 

 

 

—

 

 

 

650

 

Loss on early debt extinguishment

 

 

—

 

 

 

621

 

 

 

—

 

 

 

621

 

Total adjustments

 

 

5,686

 

 

 

2,446

 

 

 

13,914

 

 

 

7,128

 

Non-GAAP net loss attributable to common stockholders

 

$

(22,752

)

 

$

(16,328

)

 

$

(69,549

)

 

$

(43,814

)

 

 

 

 

Use of Non-GAAP Financial Measures

We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.

“Non-GAAP net loss attributable to common stockholders” is not based on any standardized methodology prescribed by GAAP and represent GAAP net loss adjusted to exclude (1) stock-based compensation expense, (2) accretion of term loan (interest expense related to ALX Oncology’s amortization of debt discount), (3) mark-to-market adjustment on financial instruments (which include preferred stock warrants and derivatives) and (4) loss on early debt extinguishment. Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

Investor Contact:

Peter Garcia

Chief Financial Officer, ALX Oncology

(650) 466-7125 Ext. 113

peter@alxoncology.com

Argot Partners

(212)-600-1902

alxoncology@argotpartners.com

Media Contact:

Karen Sharma

MacDougall

(781) 235-3060

alx@macbiocom.com

 

 GRAPHIC 3 gerappfhwdnu000001.jpg GRAPHIC begin 644 gerappfhwdnu000001.jpg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alxo-20220228.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 alxo-20220228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 alxo-20220228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 28, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 28, 2022
Entity Registrant Name ALX ONCOLOGY HOLDINGS INC
Entity Central Index Key 0001810182
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39386
Entity Incorporation State Country Code DE
Entity Tax Identification Number 85-0642577
Entity Address, Address Line One 323 Allerton Avenue
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 466-7125
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ALXO
Security Exchange Name NASDAQ
XML 8 alxo-8k_20220228_htm.xml IDEA: XBRL DOCUMENT 0001810182 2022-02-28 2022-02-28 false 0001810182 8-K 2022-02-28 ALX ONCOLOGY HOLDINGS INC DE 001-39386 85-0642577 323 Allerton Avenue South San Francisco CA 94080 (650) 466-7125 false false false false Common Stock, $0.001 par value per share ALXO NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports alxo-8k_20220228.htm alxo-20220228.xsd alxo-20220228_lab.xml alxo-20220228_pre.xml alxo-ex991_6.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alxo-8k_20220228.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "alxo-8k_20220228.htm" ] }, "labelLink": { "local": [ "alxo-20220228_lab.xml" ] }, "presentationLink": { "local": [ "alxo-20220228_pre.xml" ] }, "schema": { "local": [ "alxo-20220228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alxo", "nsuri": "http://www.alxoncology.com/20220228", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "alxo-8k_20220228.htm", "contextRef": "C_0001810182_20220228_20220228", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "alxo-8k_20220228.htm", "contextRef": "C_0001810182_20220228_20220228", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.alxoncology.com/20220228/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001564590-22-007361-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-007361-xbrl.zip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